A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in patients with advanced head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, and cholangiocarcinoma.The main questions it aims to answer are:is the new drug plus standard treatment safe and tolerableis the new drug plus standard treatment more effective than standard treatment

Inclusion Criteria:Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1Life expectancy ≥ 3 monthsAt least one measurable metastatic lesion as assessed by RECIST 1.1Adequate organ and marrow functionAdequate contraceptionPatients with any of the following:Histologically confirmed recurrent or metastatic HNSCC that is unresectable or considered incurable by local therapies and that has progressed after first-line immunotherapy. The eligible primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx. Patients may not have primary tumor sites of the skin, paranasal sinuses, or the nasopharynx (any histology).Histologically or cytologically confirmed locally advanced unresectable or metastatic ESCC. ESCC subjects have documented clinical or radiographic disease progression by RECIST 1.1 after first-line immunotherapy.Pathologically confirmed metastatic or unresectable cholangiocarcinoma or gallbladder carcinoma (GBC), with no prior systemic chemotherapy or targeted therapy or loco-regional therapy (including but not limited to transarterial chemoembolization, transarterial embolization, transarterial chemotherapy or transarterial radioembolization). Patients with recurrent disease more than 6 months after completion of adjuvant chemotherapy following curative resection are eligible.Exclusion Criteria:Any condition or comorbidity that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results, including but not limited to:Any major surgery or irradiation less than 4 weeks prior to baseline disease assessmentActive infection requiring systemic therapyKnown active hepatitis B virus, hepatitis C virus, or HIV infectionActive tuberculosis as defined per local guidanceAny other active infection (viral, fungal, or bacterial) requiring systemic therapyHistory of allogeneic tissue/solid organ transplantPrior malignancy requiring active treatment within the previous 3 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breastClinically significant or symptomatic cardiovascular/cerebrovascular disease (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) within 6 months before randomizationTreatment in another interventional clinical study within the last 1 yearHistory or clinical evidence of symptomatic central nervous system (CNS) metastasesHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy for unresectable or metastatic HNSCC or ESCCFor cholangiocarcinoma, active autoimmune disease that might deteriorate when receiving an immune-stimulatory agent. Patients with Type 1 diabetes, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible.